GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Short Percentage of Float

Shire (SHPG) Short Percentage of Float


View and export this data going back to 1998. Start your Free Trial

What is Shire Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Shire's Short Percentage of Float

For the Biotechnology subindustry, Shire's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shire's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Shire's Short Percentage of Float falls into.


Shire (SHPG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Short Percentage of Float
Comparable Companies
VRTX REGN ASX:CSL ALXN XKRX:207940 SGEN INCY XKRX:068270 HKSE:01177 XBRU:UCB OCSE:GMAB HKSE:02269 BMRN HKSE:06160 XAMS:GLPG ALNY ARRY NBIX SZSE:300122 IONS
Traded in Other Exchanges
N/A
Address
Website
http://www.shire.com
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

FDA approves Shire's Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)

By Marketwired Marketwired • 12-17-2018

U.S. FDA Accepts for Filing Shire's Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome

By Marketwired Marketwired • 11-13-2018

Shire plc: JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema  

By Marketwired Marketwired • 11-27-2018

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

By Marketwired Marketwired • 08-24-2018

Shire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

By PRNewswire PRNewswire • 09-11-2018

Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema

By Marketwired Marketwired • 11-30-2018

Shire Announces Cash Tender Offers for up to $2,250,000,000 Outstanding Principal Amount of Notes

By PRNewswire PRNewswire • 08-24-2018

Takeda Closes In on Shire, But It's Not a Done Deal Yet

By John Engle John Engle • 05-08-2018

FDA Advisory Committee Recommends Approval of Shire's Prucalopride (SHP555) for Chronic Idiopathic Constipation

By Marketwired Marketwired • 10-19-2018

Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia

By Marketwired Marketwired • 10-25-2018